Cyprotex invests for new markets at Alderley Park

CYPROTEX, the Macclesfield-based drug analysis specialist, is investing in its new space at the BioHub at Alderley Park.

In a stock market statement it said it was expanding its bioanalytical capabilities at the new science cluster near Alderley Edge which is being vacated by AstraZeneca.

The new instruments include a Waters mass spectrometer, a LabLogic radiochemical detector and a Waters atmospheric pressure gas chromatography system.

Cyprotex said the equipment would enable it to improve its services to its existing pharmaceutical customers as well as “unlock future potential” in new markets such as the chemical and personal care markets. It did not put a figure on the investment.

Dr Anthony Baxter, Cyprotex’s chief executive, said: “Characterising the structural identity of drug metabolites is a critical part of the drug development process. By investing in the QTof and the radiochemical detector we can now provide a comprehensive service which is appropriate for late stage preclinical development projects required by the regulatory authorities.

“As we expand into new markets we are observing a shift in the requirements for bioanalysis, and we are adapting our business accordingly. We now have a wide range of solutions to cover our differing customers’ needs, allowing us to grow our existing business as well as attract customers from new markets.”